首页 > 最新文献

Archivos De Bronconeumologia最新文献

英文 中文
The Role of miR-320d in Regulation of Cigarette Smoke-Induced Pro-Inflammatory Responses in COPD miR-320d在COPD患者吸烟诱导的促炎反应中的调控作用
IF 9.2 3区 医学 Q1 RESPIRATORY SYSTEM Pub Date : 2026-02-01 Epub Date: 2025-07-05 DOI: 10.1016/j.arbres.2025.06.015
Mirjam P. Roffel , Corry-Anke Brandsma , Alen Faiz , Marnix R. Jonker , Wim Timens , Guy F. Joos , Guy G. Brusselle , Tania Maes , Ken R. Bracke , Maarten van den Berge , Irene H. Heijink

Introduction

The mechanisms driving abnormal pro-inflammatory responses to cigarette smoke in COPD remain unclear. MicroRNA (miR)-320d was previously shown to have anti-inflammatory effects, being upregulated by inhaled corticosteroids. Therefore, our objective was to study whether miR-320d suppresses smoke-induced airway epithelial pro-inflammatory responses and if this is compromised in COPD.

Methods

We investigated the anti-inflammatory mechanisms of miR-320d in cigarette smoke extract (CSE)-exposed primary bronchial epithelial cells (PBECs), comparing COPD and control cells using a miR-320d mimic. Additionally, we assessed whether miR-320d expression is altered with COPD and its severity, investigating lung tissue from two independent cohorts of non-COPD controls (non/current/ex-smokers) and COPD patients (current/ex-smokers) with mild/moderate and severe disease.

Results

MiR-320d overexpression attenuated baseline and CSE-induced pro-inflammatory CXCL8, IL-1α and GM-CSF secretion in non-COPD-derived PBECs. This effect was not observed for CXCL8 and IL-1α in COPD-derived PBECs. RNA-sequencing showed that miR-320d significantly regulates the expression of 137 genes in CSE-exposed epithelium, the upregulated genes being enriched in “interleukin-33-mediated signaling” and the downregulated genes in “response to cytokine” (including IRAK1) pathways. Higher miR-320d levels were associated with lower IRAK1 expression in control but not COPD-derived PBECs. Finally, miR-320d levels were lower in lung tissue of COPD patients vs non-smoking controls and in severe vs mild/moderate COPD patients.

Conclusions

miR-320d's suppressive effect on bronchial epithelial pro-inflammatory responses cells may be compromised in COPD. Additionally, miR-320d expression in lung tissue was lower with COPD severity. Thus, lower miR-320d anti-inflammatory action may contribute to persisting inflammation in COPD.
慢性阻塞性肺病患者吸烟引起异常促炎反应的机制尚不清楚。MicroRNA (miR)-320d先前被证明具有抗炎作用,被吸入皮质类固醇上调。因此,我们的目的是研究miR-320d是否抑制烟雾诱导的气道上皮促炎反应,以及这种作用是否在COPD中受到损害。方法:我们研究了miR-320d在香烟烟雾提取物(CSE)暴露的原代支气管上皮细胞(PBECs)中的抗炎机制,使用miR-320d模拟物比较COPD和对照细胞。此外,我们评估了miR-320d表达是否随COPD及其严重程度而改变,研究了两个独立队列的肺组织,分别是轻度/中度和重度疾病的非COPD对照组(非/当前/戒烟者)和COPD患者(当前/戒烟者)。结果:在非copd源性PBECs中,MiR-320d过表达减弱了基线和cse诱导的促炎CXCL8、IL-1α和GM-CSF分泌。在copd衍生的PBECs中,CXCL8和IL-1α未观察到这种作用。rna测序结果显示,miR-320d显著调控cse暴露上皮中137个基因的表达,上调的基因富集于“白细胞介素-33介导的信号通路”,下调的基因富集于“细胞因子应答”(包括IRAK1)通路。在对照组中,较高的miR-320d水平与较低的IRAK1表达相关,但与copd衍生的PBECs无关。最后,COPD患者肺组织中miR-320d水平低于非吸烟对照组,重度COPD患者肺组织中miR-320d水平低于轻度/中度COPD患者肺组织中miR-320d水平。结论:miR-320d对支气管上皮促炎反应细胞的抑制作用可能在COPD中受损。此外,miR-320d在肺组织中的表达随COPD严重程度的降低而降低。因此,较低的miR-320d抗炎作用可能有助于COPD的持续炎症。
{"title":"The Role of miR-320d in Regulation of Cigarette Smoke-Induced Pro-Inflammatory Responses in COPD","authors":"Mirjam P. Roffel ,&nbsp;Corry-Anke Brandsma ,&nbsp;Alen Faiz ,&nbsp;Marnix R. Jonker ,&nbsp;Wim Timens ,&nbsp;Guy F. Joos ,&nbsp;Guy G. Brusselle ,&nbsp;Tania Maes ,&nbsp;Ken R. Bracke ,&nbsp;Maarten van den Berge ,&nbsp;Irene H. Heijink","doi":"10.1016/j.arbres.2025.06.015","DOIUrl":"10.1016/j.arbres.2025.06.015","url":null,"abstract":"<div><h3>Introduction</h3><div>The mechanisms driving abnormal pro-inflammatory responses to cigarette smoke in COPD remain unclear. MicroRNA (miR)-320d was previously shown to have anti-inflammatory effects, being upregulated by inhaled corticosteroids. Therefore, our objective was to study whether miR-320d suppresses smoke-induced airway epithelial pro-inflammatory responses and if this is compromised in COPD.</div></div><div><h3>Methods</h3><div>We investigated the anti-inflammatory mechanisms of miR-320d in cigarette smoke extract (CSE)-exposed primary bronchial epithelial cells (PBECs), comparing COPD and control cells using a miR-320d mimic. Additionally, we assessed whether miR-320d expression is altered with COPD and its severity, investigating lung tissue from two independent cohorts of non-COPD controls (non/current/ex-smokers) and COPD patients (current/ex-smokers) with mild/moderate and severe disease.</div></div><div><h3>Results</h3><div>MiR-320d overexpression attenuated baseline and CSE-induced pro-inflammatory CXCL8, IL-1α and GM-CSF secretion in non-COPD-derived PBECs. This effect was not observed for CXCL8 and IL-1α in COPD-derived PBECs. RNA-sequencing showed that miR-320d significantly regulates the expression of 137 genes in CSE-exposed epithelium, the upregulated genes being enriched in “interleukin-33-mediated signaling” and the downregulated genes in “response to cytokine” (including <em>IRAK1</em>) pathways. Higher miR-320d levels were associated with lower <em>IRAK1</em> expression in control but not COPD-derived PBECs. Finally, miR-320d levels were lower in lung tissue of COPD patients <em>vs</em> non-smoking controls and in severe <em>vs</em> mild/moderate COPD patients.</div></div><div><h3>Conclusions</h3><div>miR-320d's suppressive effect on bronchial epithelial pro-inflammatory responses cells may be compromised in COPD. Additionally, miR-320d expression in lung tissue was lower with COPD severity. Thus, lower miR-320d anti-inflammatory action may contribute to persisting inflammation in COPD.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 2","pages":"Pages 86-93"},"PeriodicalIF":9.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inclusion of the Intermediate Respiratory Care Unit as a Detection Area for Controlled Donation After Circulatory Death: Results of a Pilot Project 将中级呼吸护理病房作为循环性死亡后控制捐献的检测区域:一个试点项目的结果。
IF 9.2 3区 医学 Q1 RESPIRATORY SYSTEM Pub Date : 2026-02-01 Epub Date: 2025-07-05 DOI: 10.1016/j.arbres.2025.07.004
Alejandro Romero-Linares , Antonio Cárdenas-Cruz , Jose M. Pérez-Villares , Jose A. Sánchez-Martínez , Patricia Fuentes-García , Bernardino Alcázar-Navarrete
{"title":"Inclusion of the Intermediate Respiratory Care Unit as a Detection Area for Controlled Donation After Circulatory Death: Results of a Pilot Project","authors":"Alejandro Romero-Linares ,&nbsp;Antonio Cárdenas-Cruz ,&nbsp;Jose M. Pérez-Villares ,&nbsp;Jose A. Sánchez-Martínez ,&nbsp;Patricia Fuentes-García ,&nbsp;Bernardino Alcázar-Navarrete","doi":"10.1016/j.arbres.2025.07.004","DOIUrl":"10.1016/j.arbres.2025.07.004","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 2","pages":"Pages 118-120"},"PeriodicalIF":9.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Splenic Silicosis 脾矽肺病。
IF 9.2 3区 医学 Q1 RESPIRATORY SYSTEM Pub Date : 2026-02-01 Epub Date: 2025-09-02 DOI: 10.1016/j.arbres.2025.08.006
Eric Andrey Rodríguez-Vega, Karen Pamela Martínez-Espinosa, Ana Linet Bravo-Gutiérrez
{"title":"Splenic Silicosis","authors":"Eric Andrey Rodríguez-Vega,&nbsp;Karen Pamela Martínez-Espinosa,&nbsp;Ana Linet Bravo-Gutiérrez","doi":"10.1016/j.arbres.2025.08.006","DOIUrl":"10.1016/j.arbres.2025.08.006","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 2","pages":"Pages 141-142"},"PeriodicalIF":9.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unusual Case of Multiple and Delayed Recurrence of a Solitary Fibrous Tumor of the Pleura After Complete Resection 胸膜单发纤维性肿瘤完全切除后多发迟发的罕见病例。
IF 9.2 3区 医学 Q1 RESPIRATORY SYSTEM Pub Date : 2026-02-01 Epub Date: 2025-09-01 DOI: 10.1016/j.arbres.2025.08.007
Génesis Isabel Victoriano Soriano , Begoña Gregorio Crespo , José Soro García
{"title":"Unusual Case of Multiple and Delayed Recurrence of a Solitary Fibrous Tumor of the Pleura After Complete Resection","authors":"Génesis Isabel Victoriano Soriano ,&nbsp;Begoña Gregorio Crespo ,&nbsp;José Soro García","doi":"10.1016/j.arbres.2025.08.007","DOIUrl":"10.1016/j.arbres.2025.08.007","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 2","pages":"Pages 143-144"},"PeriodicalIF":9.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145051538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhaled Corticosteroid Reduction Effects on Asthma Outcomes After Three Years of Benralizumab Treatment in Severe Asthma Patients 吸入皮质类固醇减少对严重哮喘患者贝那利珠单抗治疗3年后哮喘结局的影响。
IF 9.2 3区 医学 Q1 RESPIRATORY SYSTEM Pub Date : 2026-02-01 Epub Date: 2025-09-01 DOI: 10.1016/j.arbres.2025.08.001
Marta Arteaga , Laura López-Duque , Daniel Laorden , Inés Torrado , David Romero-Ribate , Elena Villamañán , Santiago Quirce , Rodolfo Álvarez-Sala , Javier Domínguez-Ortega
{"title":"Inhaled Corticosteroid Reduction Effects on Asthma Outcomes After Three Years of Benralizumab Treatment in Severe Asthma Patients","authors":"Marta Arteaga ,&nbsp;Laura López-Duque ,&nbsp;Daniel Laorden ,&nbsp;Inés Torrado ,&nbsp;David Romero-Ribate ,&nbsp;Elena Villamañán ,&nbsp;Santiago Quirce ,&nbsp;Rodolfo Álvarez-Sala ,&nbsp;Javier Domínguez-Ortega","doi":"10.1016/j.arbres.2025.08.001","DOIUrl":"10.1016/j.arbres.2025.08.001","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 2","pages":"Pages 130-132"},"PeriodicalIF":9.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of Quality of Life at the End of Life in Patients Undergoing Home Mechanical Ventilation. 家用机械通气患者生命末期生活质量评估。
IF 9.2 3区 医学 Q1 RESPIRATORY SYSTEM Pub Date : 2026-01-31 DOI: 10.1016/j.arbres.2026.01.017
Maria João Oliveira, Mafalda Pais, Pedro Viegas, Leonor Roseta, Carla Nogueira, Sara Conde, Ana Machado, Carla Ribeiro
{"title":"Assessment of Quality of Life at the End of Life in Patients Undergoing Home Mechanical Ventilation.","authors":"Maria João Oliveira, Mafalda Pais, Pedro Viegas, Leonor Roseta, Carla Nogueira, Sara Conde, Ana Machado, Carla Ribeiro","doi":"10.1016/j.arbres.2026.01.017","DOIUrl":"https://doi.org/10.1016/j.arbres.2026.01.017","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":" ","pages":""},"PeriodicalIF":9.2,"publicationDate":"2026-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146218312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unexpected Spontaneous Expectoration of an Endobronchial Squamous Cell Carcinoma. 支气管内鳞状细胞癌的意外自发性咳痰。
IF 9.2 3区 医学 Q1 RESPIRATORY SYSTEM Pub Date : 2026-01-31 DOI: 10.1016/j.arbres.2026.01.016
Haowei Lu, Feiyang Li, Dong Zhao
{"title":"Unexpected Spontaneous Expectoration of an Endobronchial Squamous Cell Carcinoma.","authors":"Haowei Lu, Feiyang Li, Dong Zhao","doi":"10.1016/j.arbres.2026.01.016","DOIUrl":"https://doi.org/10.1016/j.arbres.2026.01.016","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":" ","pages":""},"PeriodicalIF":9.2,"publicationDate":"2026-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147300998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rethinking GOLD E: The Significance of a Single Moderate Exacerbation in COPD. 重新思考GOLD E: COPD单一中度加重的意义。
IF 9.2 3区 医学 Q1 RESPIRATORY SYSTEM Pub Date : 2026-01-30 DOI: 10.1016/j.arbres.2026.01.011
Marc Miravitlles

The new GOLD 2026 classification includes, for the first time, patients who experience one moderate exacerbation in a year in the E category. This change may have substantial implications, as patients with one moderate exacerbation are more frequent than those with two or more moderate exacerbations or at least one severe exacerbation considered together, according to population-based studies. This reclassification implies that patients with one moderate exacerbation and elevated blood eosinophil counts may initiate triple therapy, and, by being classified as GOLD E, may become candidates for second-line preventive treatments, despite GOLD recommendations for escalation only after two or more moderate exacerbations or one severe exacerbation. The rationale for classifying patients with one moderate exacerbation as GOLD E should rely on evidence of the clinical impact of a single moderate exacerbation and the associated increased risk of poor outcomes. This review summarises evidence from large trials and epidemiological studies regarding these aspects and proposes a pragmatic approach to management for patients with one moderate exacerbation. In conclusion, the impact of a single moderate exacerbation is limited at a population level and although the risk of future exacerbations is higher than in patients with none, it remains low, usually below 50%. Decisions regarding escalation or initiation of preventive therapy in COPD should be individualised, considering additional risk factors such as age, symptom burden, lung function impairment, and comorbidities, as well as patient preferences and values.

新的GOLD 2026分类首次将一年内经历一次中度恶化的患者纳入E类。这一变化可能具有重大意义,因为根据基于人群的研究,一次中度急性发作的患者比两次或两次以上中度急性发作或至少一次严重急性发作的患者更频繁。这种重新分类意味着一次中度加重和嗜酸性粒细胞计数升高的患者可以开始三联治疗,并且由于被分类为GOLD E,可能成为二线预防性治疗的候选者,尽管GOLD建议只有在两次或两次以上中度加重或一次严重加重后才升级。将一次中度加重的患者分类为GOLD E级的基本原理应依赖于单一中度加重的临床影响和相关不良结局风险增加的证据。本综述总结了关于这些方面的大型试验和流行病学研究的证据,并提出了一种实用的方法来管理一次中度恶化的患者。总之,单次中度加重的影响在人群水平上是有限的,尽管未来加重的风险高于无加重的患者,但仍然很低,通常低于50%。COPD预防治疗升级或开始的决定应个体化,考虑其他风险因素,如年龄、症状负担、肺功能损害和合并症,以及患者的偏好和价值观。
{"title":"Rethinking GOLD E: The Significance of a Single Moderate Exacerbation in COPD.","authors":"Marc Miravitlles","doi":"10.1016/j.arbres.2026.01.011","DOIUrl":"https://doi.org/10.1016/j.arbres.2026.01.011","url":null,"abstract":"<p><p>The new GOLD 2026 classification includes, for the first time, patients who experience one moderate exacerbation in a year in the E category. This change may have substantial implications, as patients with one moderate exacerbation are more frequent than those with two or more moderate exacerbations or at least one severe exacerbation considered together, according to population-based studies. This reclassification implies that patients with one moderate exacerbation and elevated blood eosinophil counts may initiate triple therapy, and, by being classified as GOLD E, may become candidates for second-line preventive treatments, despite GOLD recommendations for escalation only after two or more moderate exacerbations or one severe exacerbation. The rationale for classifying patients with one moderate exacerbation as GOLD E should rely on evidence of the clinical impact of a single moderate exacerbation and the associated increased risk of poor outcomes. This review summarises evidence from large trials and epidemiological studies regarding these aspects and proposes a pragmatic approach to management for patients with one moderate exacerbation. In conclusion, the impact of a single moderate exacerbation is limited at a population level and although the risk of future exacerbations is higher than in patients with none, it remains low, usually below 50%. Decisions regarding escalation or initiation of preventive therapy in COPD should be individualised, considering additional risk factors such as age, symptom burden, lung function impairment, and comorbidities, as well as patient preferences and values.</p>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":" ","pages":""},"PeriodicalIF":9.2,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146197318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Respiratory Syncytial Virus in Pediatrics: Update on Epidemiology, Management, Long-term Consequences and Prevention. Consensus From Asociación Latinoamericana de Tórax (ALAT) 2025. 儿科呼吸道合胞体病毒:流行病学、管理、长期后果和预防的最新进展。Asociación Latinoamericana de Tórax (ALAT) 2025的共识。
IF 9.2 3区 医学 Q1 RESPIRATORY SYSTEM Pub Date : 2026-01-30 DOI: 10.1016/j.arbres.2026.01.009
Manuel Enrique Soto-Martínez, Ranniery Acuña Cordero, Andrea Parra-Buitrago, Oscar Baron, Guillermo Zepeda, Jose Antonio Castro-Rodriguez, Luis Alam, Carlos Juarez-Ortiz, Luis A Rosal-Palomo, Lydiana Avila

Respiratory syncytial virus (RSV) represents a major global public health challenge, with an especially high burden in low- and middle-income countries, many of which are located in Latin America. Worldwide, RSV is the leading cause of hospitalization in infants and young children due to lower respiratory tract infections (LRTIs). Beyond the acute illness, severe RSV disease is associated with substantial long-term respiratory morbidity, including recurrent wheezing and an increased risk of asthma later in childhood. These consequences underscore the significant clinical, social, and economic impact of RSV on children, families, and health systems, particularly in regions where healthcare access and surveillance infrastructure remain limited.

呼吸道合胞病毒(RSV)是一项重大的全球公共卫生挑战,在低收入和中等收入国家造成的负担尤其沉重,其中许多国家位于拉丁美洲。在世界范围内,呼吸道合胞病毒是婴幼儿因下呼吸道感染(LRTIs)住院的主要原因。除了急性疾病外,严重的呼吸道合胞病毒疾病还与大量的长期呼吸道疾病相关,包括复发性喘息和儿童后期哮喘风险增加。这些后果强调了呼吸道合胞病毒对儿童、家庭和卫生系统的重大临床、社会和经济影响,特别是在卫生保健可及性和监测基础设施仍然有限的地区。
{"title":"Respiratory Syncytial Virus in Pediatrics: Update on Epidemiology, Management, Long-term Consequences and Prevention. Consensus From Asociación Latinoamericana de Tórax (ALAT) 2025.","authors":"Manuel Enrique Soto-Martínez, Ranniery Acuña Cordero, Andrea Parra-Buitrago, Oscar Baron, Guillermo Zepeda, Jose Antonio Castro-Rodriguez, Luis Alam, Carlos Juarez-Ortiz, Luis A Rosal-Palomo, Lydiana Avila","doi":"10.1016/j.arbres.2026.01.009","DOIUrl":"https://doi.org/10.1016/j.arbres.2026.01.009","url":null,"abstract":"<p><p>Respiratory syncytial virus (RSV) represents a major global public health challenge, with an especially high burden in low- and middle-income countries, many of which are located in Latin America. Worldwide, RSV is the leading cause of hospitalization in infants and young children due to lower respiratory tract infections (LRTIs). Beyond the acute illness, severe RSV disease is associated with substantial long-term respiratory morbidity, including recurrent wheezing and an increased risk of asthma later in childhood. These consequences underscore the significant clinical, social, and economic impact of RSV on children, families, and health systems, particularly in regions where healthcare access and surveillance infrastructure remain limited.</p>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":" ","pages":""},"PeriodicalIF":9.2,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146224790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination Therapy in Pulmonary Fibrosis: A New Era. 联合治疗肺纤维化:一个新时代。
IF 9.2 3区 医学 Q1 RESPIRATORY SYSTEM Pub Date : 2026-01-30 DOI: 10.1016/j.arbres.2026.01.012
Fabrizio Luppi, Giovanni Ferrara, Carlo Vancheri
{"title":"Combination Therapy in Pulmonary Fibrosis: A New Era.","authors":"Fabrizio Luppi, Giovanni Ferrara, Carlo Vancheri","doi":"10.1016/j.arbres.2026.01.012","DOIUrl":"https://doi.org/10.1016/j.arbres.2026.01.012","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":" ","pages":""},"PeriodicalIF":9.2,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146194017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Archivos De Bronconeumologia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1